Induction therapy in renal transplant recipients: A review

Immunological Investigations

Volumn 43, Issue 8, 2014, Pages 790-806

  Laftavi, Mark Reza ^a   Sharma, Rajeev ^a   Feng, Lin ^a   Said, Meriem ^a   Pankewycz, Oleh ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Induction; Kidney; Transplantation

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; RABBIT ANTITHYMOCYTE GLOBULIN; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

AFRICAN AMERICAN; CELL LOSS; DRUG COST; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; NONHUMAN; OPPORTUNISTIC INFECTION; REVIEW; SENESCENCE; UNITED STATES; ANIMAL; GRAFT REJECTION; INDUCTION CHEMOTHERAPY; LYMPHOCYTE DEPLETION; PERSONALIZED MEDICINE; PROCEDURES; RISK ASSESSMENT;

ANIMALS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; INDIVIDUALIZED MEDICINE; INDUCTION CHEMOTHERAPY; KIDNEY TRANSPLANTATION; LYMPHOCYTE DEPLETION; RISK ASSESSMENT;

EID: 84911074397     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2014.914326     Document Type: Review

References (101)

1. Abbott KC, Lentine KL, Bucci JR, et al. (2004). The impact of transplantation with deceased donor hepatitis c-positive kidneys on survival in wait-listed long-term dialysis patients. Am J Transplant, 4, 2032-7.
2. Al Najjar A, Etienne I, Le Pogamp P, et al. (2006). Long-term results of monoclonal anti-Il2-receptor antibody versus polyclonal antilymphocyte antibodies as induction therapy in renal transplantation. Transplant Proc, 38, 2298-9.
3. Barger BO, Hudson SL, Shroyer TW, et al. (1987). Influence of race on renal allograft survival in the pre- and postcyclosporine era. Clin Transpl, 217-33. http://www.ncbi.nlm.nih.gov/pubmed/3154405.
4. Barth R, Gurk-Turner C, Klassen D, et al. (2008). Successful Alemtuzumab induction and steroid withdrawal in African American and Caucasian recipients of renal transplants: 1980. Transplantation, 86, 651.
5. Basar H, Soran A, Shapiro R, et al. (1999). Renal transplantation in recipients over the age of 60: The impact of donor age. Transplantation, 67, 1191-3.
6. Beiras-Fernandez A, Chappell D, Hammer C, Thein E. (2006). Influence of polyclonal anti-thymocyte globulins upon ischemia-reperfusion injury in a non-human primate model. Transpl Immunol, 15, 273-9.
7. Bogetti D, Jarzembowski TM, Sankary HN, et al. (2005a). Hepatic ischemia/reperfusion injury can be modulated with thymoglobulin induction therapy. Transplant Proc, 37, 404-6.
8. Bogetti D, Sankary HN, Jarzembowski TM, et al. (2005b). Thymoglobulin induction protects liver allografts from ischemia/reperfusion injury. Clin Transplant, 19, 507-11.
9. Bonnefoy-Berard N, Flacher M, Revillard JP. (1992). Antiproliferative effect of antilymphocyte globulins on B cells and B-cell lines. Blood, 79, 2164-70.
10. Brennan DC, Daller JA, Lake KD, et al. (2006). Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med, 355, 1967-77.
11. Brennan DC, Schnitzler MA. (2008). Long-term results of rabbit antithymocyte globulin and basiliximab induction. N Engl J Med, 359, 1736-8.
12. Bunnapradist S, Takemoto SK. (2005). Multivariate analysis of antibody induction therapy and their associated outcomes in deceased donor transplants. Transplant Proc, 37(2), 889-91.
13. Cai J, Terasaki PI. (2010). Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: An analysis of United Network for Organ Sharing registry data. Transplantation, 90, 1511-15.
14. Chappell D, Beiras-Fernandez A, Hammer C, Thein E. (2006). In vivo visualization of the effect of polyclonal antithymocyte globulins on the microcirculation after ischemia/reperfusion in a primate model. Transplantation, 81, 552-8.
15. Chertow GM, Milford EL. (1997). Poorer graft survival in African-American transplant recipients cannot be explained by HLA mismatching. Adv Ren Replace Ther, 4, 40-5.
16. Cornell LD, Smith RN, Colvin RB. (2008). Kidney transplantation: Mechanisms of rejection and acceptance. Annu Rev Pathol, 3, 189-220.
17. Czesnikiewicz-Guzik M, Lee WW, Cui D, et al. (2008). T cell subset-specific susceptibility to aging. Clin Immunol, 127, 107-18.
18. Deeks ED, Keating GM. (2009). Rabbit antithymocyte globulin (thymoglobulin): A review of its use in the prevention and treatment of acute renal allograft rejection. Drugs, 69, 1483-512.
19. Eckhoff DE, Young CJ, Gaston RS, et al. (2007). Racial disparities in renal allograft survival: A public health issue? J Am Coll Surg, 204, 894-902; discussion 902-3.
20. Farney AC, Doares W, Rogers J, et al. (2009). A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Transplantation, 88, 810-19.
21. Farney A, Sundberg A, Moore P, et al. (2008). A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation. Clin Transplant, 22, 41-9.
22. Friend PJ, Hale G, Waldmann H, et al. (1989). Campath-1M-prophylactic use after kidney transplantation. A randomized controlled clinical trial. Transplantation, 48, 248-53.
23. Friend PJ, Waldmann H, Hale G, et al. (1991). Reversal of allograft rejection using the monoclonal antibody, Campath-1G. Transplant Proc, 23, 2253-4.
24. Gaston RS, Ayres I, Dooley LG, Diethelm AG. (1993). Racial equity in renal transplantation. The disparate impact of HLA-based allocation. JAMA, 270, 1352-6.
25. Gill J, Sampaio M, Gill JS, et al. (2011). Induction immunosuppressive therapy in the elderly kidney transplant recipient in the United States. Clin J Am Soc Nephrol, 6, 1168-78.
26. Hale G, Waldmann H, Friend P, Calne R. (1986). Pilot study of CAMPATH-1, a rat monoclonal antibody that fixes human complement, as an immunosuppressant in organ transplantation. Transplantation, 42, 308-11.
27. Halloran PF. (2004). Immunosuppressive drugs for kidney transplantation. N Engl J Med, 351, 2715-29.
28. Hammond EB, Taber DJ, Weimert NA, et al. (2010). Efficacy of induction therapy on acute rejection and graft outcomes in African American kidney transplantation. Clin Transplant, 24, 40-7.
29. Hanaway MJ, Woodle ES, Mulgaonkar S, et al. (2011). Alemtuzumab induction in renal transplantation. N Engl J Med, 364, 1909-19.
30. Hardinger KL. (2006). Rabbit antithymocyte globulin induction therapy in adult renal transplantation. Pharmacotherapy, 26, 1771-83.
31. Held PJ, Kahan BD, Hunsicker LG, et al. (1994). The impact of HLA mismatches on the survival of first cadaveric kidney transplants. N Engl J Med, 331, 765-70.
32. Heldal K, Hartmann A, Leivestad T, et al. (2011). Risk variables associated with the outcome of kidney recipients >70 years of age in the new millennium. Nephrol Dial Transplant, 26, 2706-11.
33. Hestin D, Frimat L, Hubert J, et al. (1994). Renal transplantation in patients over sixty years of age. Clin Nephrol, 42, 232-6.
34. Hocker B, Tonshoff B. (2011). Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: A viable option? Paediatr Drugs, 13, 49-69.
35. Hurst FP, Altieri M, Nee R, et al. (2011). Poor outcomes in elderly kidney transplant recipients receiving alemtuzumab induction. Am J Nephrol, 34, 534-41.
36. Hussain SM, Sureshkumar KK, Ko TY, Marcus RJ. (2013). Effect of induction agent on posttransplant outcomes in deceased donor kidney transplant recipients: Influence of race. Transplant Proc, 45, 119-21.
37. Hutchings A, Purcell WM, Benfield MR. (1999). Increased B7 Expression by antigen presenting cells from African-Americans. Transplantation, 67, S40.
38. Ismail N, Hakim RM, Helderman JH. (1994). Renal replacement therapies in the elderly: Part II. Renal transplantation. Am J Kidney Dis, 23, 1-15.
39. Jassal SV, Opelz G, Cole E. (1997). Transplantation in the elderly: A review. Geriatr Nephrol Urol, 7, 157-65.
40. Jindal RM, Das NP, Neff RT, et al. (2009). Outcomes in African-Americans vs. Caucasians using thymoglobulin or interleukin-2 receptor inhibitor induction: Analysis of USRDS database. Am J Nephrol, 29, 501-8.
41. Kaabak MM, Babenko NN, Samsonov DV, et al. (2013). Alemtuzumab induction in pediatric kidney transplantation. Pediatr Transplant, 17, 168-78.
42. Kahan BD, Rajagopalan PR, Hall M. (1999). Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation, 67, 276-84.
43. Kamar N, Rostaing L, Selves J, et al. (2005). Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am J Transplant, 5, 1704-12.
44. Katznelson S, Gjertson DW, Cecka JM. (1995). The effect of race and ethnicity on kidney allograft outcome. Clin Transpl, 379-94. http://www.ncbi.nlm.nih.gov/pubmed/8794281.
45. Kerman RH, Kimball PM, Van Buren CT, et al. (1991). Possible contribution of pretransplant immune responder status to renal allograft survival differences of black versus white recipients. Transplantation, 51, 338-42.
46. Kerman RH, Kimball PM, Van Buren CT, et al. (1992). Influence of race on crossmatch outcome and recipient eligibility for transplantation. Transplantation, 53, 64-7.
47. Kirk AD, Hale DA, Swanson SJ, Mannon RB. (2006). Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab. Am J Transplant, 6, 1084-5.
48. Knechtle SJ, Pirsch Jr. JD, Fechner H, et al. (2003). Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant no, 3, 722-30.
49. Knight SR, Morris PJ. (2010). Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation, 89, 1-14.
50. Kumar MS, Xiao SG, Fyfe B, et al. (2005). Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsies. Clin Transplant, 19, 61-9.
51. Kyllonen LE, Eklund BH, Pesonen EJ, Salmela KT. (2007). Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: Efficacy and safety. Transplantation, 84, 75-82.
52. Laftavi MR, Pankewycz O, Patel S, et al. (2013). African American renal transplant recipients (RTR) require higher tacrolimus doses to achieve target levels compared to white RTR: Does clotrimazole help? Transplant Proc, 45, 3498-501.
53. Laftavi MR, Patel S, Soliman MP, et al. (2011). Low-dose thymoglobulin use in elderly renal transplant recipients is safe and effective induction therapy. Transplant Proc, 43, 466-8.
54. Laftavi MR, Stephan R, Stefanick B, et al. (2005). Randomized prospective trial of early steroid withdrawal compared with low-dose steroids in renal transplant recipients using serial protocol biopsies to assess efficacy and safety. Surgery, 137, 364-71.
55. Leffell MS, Steinberg AG, Bias WB, et al. (1994). The distribution of HLA antigens and phenotypes among donors and patients in the UNOS registry. Transplantation, 58, 1119-30.
56. Locke JE, James NT, Mannon RB, et al. (2014). Immunosuppression regimen and the risk of acute rejection in HIV-infected kidney transplant recipients. Transplantation, 97, 446-50.
57. Luan FL, Schaubel DE, Zhang H, et al. (2008). Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C. Transplantation, 85, 1601-6.
58. Martin SI, Marty FM, Fiumara K, et al. (2006). Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis, 43, 16-24.
59. Matas AJ, Smith JM, Skeans MA, et al. (2014). OPTN/SRTR 2012 Annual Data Report: Kidney. Amer J Transplant, 14, 11-44.
60. Mehrabi A, Mood A, Sadeghi ZhM, et al. (2007). Thymoglobulin and ischemia reperfusion injury in kidney and liver transplantation. Nephrol Dial Transplant, 22, viii54-60.
61. Meier-Kriesche H, Ojo AO, Arndorfer JA, et al. (2001). Need for individualized immunosuppression in elderly renal transplant recipients. Transplant Proc, 33, 1190-1.
62. Michallet MC, Preville X, Flacher M, et al. (2003). Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation, 75, 657-62.
63. Moudgil A, Puliyanda D. (2007). Induction therapy in pediatric renal transplant recipients: An overview. Paediatr Drugs, 9, 323-41.
64. Mourad G, Rostaing L, Legendre C, et al. (2004). Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation, 78, 584-90.
65. Nashan, B. (2005). Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: A comparative review. BioDrugs, 19, 39-46.
66. Nashan B, Moore R, Amlot P, et al. (1997). Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet, 350, 1193-8.
67. Naylor K, Li G, Vallejo AN, et al. (2005). The influence of age on T cell generation and TCR diversity. J Immunol, 174, 7446-52.
68. Neylan JF. (1997). Immunosuppressive therapy in high-risk transplant patients: Dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation, 64, 1277-82.
69. Norman DJ, Turka LA. (2001). Primer on transplantation, 2nd Ed. Laurel, NJ: American Society of Transplantation.
70. Nyberg G, Nilsson B, Norden G, Karlberg I. (1995). Outcome of renal transplantation in patients over the age of 60: A case-control study. Nephrol Dial Transplant, 10, 91-4.
71. Ojo AO, Port FK, Held PJ, et al. (1995). Inferior outcome of two-haplotype matched renal transplants in blacks: Role of early rejection. Kidney Int, 48, 1592-9.
72. Pankewycz O, Leca N, Kohli R, et al. (2011a). Low-dose rabbit antithymocyte globulin induction therapy results in prolonged selective lymphocyte depletion irrespective of maintenance immunosuppression. Transplant Proc, 43, 462-5.
73. Pankewycz O, Leca N, Kohli R, et al. (2011b). Conversion to low-dose tacrolimus or rapamycin 3 months after kidney transplantation: A prospective, protocol biopsyguided study. Transplant Proc, 43, 519-23.
74. Peleg AY, Husain S, Kwak EJ, et al. (2007). Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis, 44, 204-12.
75. Pescovitz MD. (2008). Use of antibody induction in pediatric renal transplantation. Curr Opin Organ Transplant, 13, 495-9.
76. Puliyanda DP, Stablein DM, Dharnidharka VR. (2007). Younger age and antibody induction increase the risk for infection in pediatric renal transplantation: A NAPRTCS report. Am J Transplant, 7, 662-6.
77. Puttarajappa C, Yabes J, Bei L, et al. (2013). Cancer risk with alemtuzumab following kidney transplantation. Clin Transplant, 27, E264-71.
78. Schold JD, Kaplan B, Chumbler NR, et al. (2005). Access to quality: Evaluation of the allocation of deceased donor kidneys for transplantation. J Am Soc Nephrol, 16, 3121-7.
79. Shaw AC, Joshi S, Greenwood H, et al. (2010). Aging of the innate immune system. Curr Opin Immunol, 22, 507-13.
80. Sollinger H, Kaplan B, Pescovitz MD, et al. (2001). Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation, 72, 1915-19.
81. Stock PG, Barin B, Murphy B, et al. (2010). Outcomes of kidney transplantation in HIVinfected recipients. N Engl J Med, 363, 2004-14.
82. Stout-Delgado HW, Du W, Shirali AC, et al. (2009). Aging promotes neutrophil-induced mortality by augmenting IL-17 production during viral infection. Cell Host Microbe, 6, 446-56.
83. Sung J, Barry JM, Jenkins R, et al. (2013). Alemtuzumab induction with tacrolimus monotherapy in 25 pediatric renal transplant recipients. Pediatr Transplant, 17, 718-25.
84. Sureshkumar KK, Thai NL, Marcus RJ. (2012). Kidney transplantation in hepatitis C-positive recipients: Does type of induction influence outcomes? Transplant Proc, 44, 1262-4.
85. Suthanthiran M, Khanna A, Cukran D, et al. (1998). Transforming growth factor-beta 1 hyperexpression in African American end-stage renal disease patients. Kidney Int, 53, 639-44.
86. Terasaki P, Mizutani K. (2006). Antibody mediated rejection: Update 2006. Clin J Am Soc Nephrol, 1, 400-3.
87. Thomas PG, Woodside KJ, Lappin JA, et al. (2007). Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Transplantation, 83, 1509-12.
88. Tran HT, Acharya MK, McKay DB, et al. (2000). Avoidance of cyclosporine in renal transplantation: Effects of daclizumab, mycophenolate mofetil, and steroids. J Am Soc Nephrol, 11, 1903-9.
89. Traum AZ, Ko DS, Kawai T. (2008). The potential for tolerance in pediatric renal transplantation. Curr Opin Organ Transplant, 13, 489-94.
90. Tullius SG, Pratschke J, Strobelt V, et al. (2003). ATG versus basiliximab induction therapy in renal allograft recipients receiving a dual immunosuppressive regimen: One-year results. Transplant Proc, 35, 2100-1.
91. U.S Renal Data System (2013). USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD, 2013.
92. Vincenti F, Ramos E, Brattstrom C, et al. (2001). Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation, 71, 1282-7.
93. Vitko S, Klinger M, Salmela K, et al. (2005). Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: Results of the Atlas study. Transplantation, 80, 1734-41.
94. Wagner SJ, Brennan DC. (2012). Induction therapy in renal transplant recipients. Drugs, 72, 671-83.
95. Yoon SC, Hurst FP, Jindal RM, et al. (2011). Trends in renal transplantation in patients with human immunodeficiency virus infection: An analysis of the United States renal data system. Transplantation, 91, 864-8.
96. Young CJ, Gaston RS. (2000). Renal transplantation in black Americans. N Engl J Med, 343, 1545-52.
97. Young CJ, Kew C. (2005). Health disparities in transplantation: Focus on the complexity and challenge of renal transplantation in African Americans. Med Clin North Am, 89, 1003-31, ix.
98. Zachariah M, Nader N, Venuto R, et al. (2012). Induction immunotherapy in the elderly kidney transplant patients - Comparisonbetween Alemtuzumab, Thymoglobulin and Basiliximab. Amer J Transplantat, 12, 315.
99. Zand MS. (2005). Immunosuppression and immune monitoring after renal transplantation. Semin Dialys, 18, 511-19.
100. Zhang X, Huang H, Han S, et al. (2012). Alemtuzumab induction in renal transplantation: A meta-analysis and systemic review. Transpl Immunol, 27, 63-8.
101. Zhou YC, Cecka JM, Terasaki PI. (1990). Effect of race on kidney transplants. Clin Transpl, 1990, 447-59.